Ninth IPO filing in 2012 - Hyperion's $57.5m - does not yet signal 'healthy' investment climate
This article was originally published in Scrip
Executive Summary
In the third biopharmaceutical initial public offering filed this month, Hyperion Therapeutics said on 13 April that it wants to raise $57.5 million in an IPO to help fund clinical development of Ravicti (glycerol phenylbutyrate) for urea cycle disorders (UCD) and hepatic encephalopathy.